Document is current

Article History

Received: 14 May 2024

Revised: 19 July 2024

Accepted: 23 July 2024

First Online: 12 August 2024

Competing interests

: CP reports consultancy for AbbVie, Amgen, Celgene (Bristol Myers Squibb), Sanofi, iTEOS Therapeutics, and Pfizer; honoraria from Amgen, Janssen, Celgene (Bristol Myers Squibb), and Sanofi; and travel support from Amgen, Janssen, and Celgene (Bristol Myers Squibb). FHS has received grants or contracts from Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Targovax, and Sanofi; payment or honoraria for lectures or speakers’ bureau participation from AbbVie, Amgen, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen, Novartis, Oncopeptides, Pfizer, Sanofi, SkylineDx, and Takeda; serving on a data safety monitoring or advisory board for AbbVie, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, and Takeda. DAC reports grants and non-financial support from Celgene Corporation, Merck, Amgen, Takeda Oncology and Sanofi; travel support from Celgene Corporation; payment to institution for educational lecture from Janssen; participation on a Data Safety Monitoring Board for a multiple myeloma study; and personal payment for meeting attendance from European Myeloma Network, Rotterdam. LJW has no conflicts to disclose. FD reports consulting fees from Janssen and participation on an advisory board for Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, and Takeda. ON reports honorarium from Pfizer; advisory board participation for BMS, Janssen, Takeda, Sanofi, GPCR Therapeutics; and research funding from Takeda, Janssen. HA reports advisory board participation for ADC Therapeutics and Genmab; grants and personal fees from Morphosys; grants from Genentech; and personal fees from Novartis, BMS, Amgen, and AbbVie. M-VM has received payment or honoraria for lectures or speakers’ bureau participation from Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Pfizer, Sanofi, and Takeda; and served on a data safety monitoring or advisory board for Amgen, BlueBird Bio, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Pfizer, Regeneron, Sanofi, and Takeda. JL has no conflicts to disclose. KW reports research grants from AbbVie, Amgen, Bristol Myers Squibb/Celgene, Janssen, GSK, Sanofi, and Takeda; honoraria from AbbVie, Amgen, Adaptive Biotech, AstraZeneca, Bristol Myers Squibb/Celgene, BeiGene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda, and Menarini; and consulting fees from AbbVie, Amgen, Adaptive Biotech, Bristol Myers Squibb/Celgene, BeiGene, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Roche, Sanofi, Takeda, and Minarini. HL reports grants or contracts from Takeda, Amgen, Sanofi; consulting fees from Celgene, Janssen-Cilag, Takeda, Amgen, BMS, Sanofi, GSK, Pfizer; honoraria from Celgene, Janssen-Cilag, Takeda, Amgen, BMS, Sanofi, GSK, Pfizer, AbbVie; and participation in data safety monitoring or advisory board of Celgene, Takeda, Amgen, BMS, Sanofi. SVR has no conflicts to disclose. PS has received grants or contracts from Amgen, Celgene, Janssen, Takeda, and SkylineDx. GJ has received honoraria and research funding from BMS/Celgene. GM has participated in advisory boards for Janssen, Bristol Myers Squibb, Celgene, Karyopharm and Oncopeptides. PGR has served on advisory committees for and received consulting fees from Astra Zeneca, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Karyopharm, Oncopeptides, Regeneron, and Sanofi; and clinical research grants from Bristol Myers Squibb/Celgene, Karyopharm, and Oncopeptides.